Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics: Rezafungin Data Could Bring Value
05:33am, Tuesday, 20'th Jul 2021
Cidara is in clinical trials with a fungus therapy and has an antiviral platform.
Cidara Therapeutics Provides Leadership Update
04:01pm, Thursday, 01'st Jul 2021
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference
08:00am, Monday, 14'th Jun 2021
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
08:26pm, Thursday, 13'th May 2021
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results
04:29pm, Thursday, 13'th May 2021
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patient
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
04:10pm, Wednesday, 05'th May 2021
Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08:00am, Wednesday, 07'th Apr 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patie
Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies
10:36am, Tuesday, 06'th Apr 2021
Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.
Why Acadia Pharma, Bio-path And Cidara Are Moving Today
09:48am, Monday, 05'th Apr 2021
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rej
Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza Candidates
08:05am, Monday, 05'th Apr 2021
Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to
Cidara Therapeutics Stock Price Increased Over 5% Pre-Market: Why It Happened
07:54am, Monday, 05'th Apr 2021
The stock price of Cidara Therapeutics, Inc. (Nasdaq: CDTX) increased by over 5% pre-market. This is why it happened.
Collaboration includes exclusive worldwide rights to Cidara's CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
04:47pm, Thursday, 25'th Feb 2021
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:59pm, Tuesday, 05'th Jan 2021
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patie
